Journal
JOURNAL OF MOLECULAR ENDOCRINOLOGY
Volume 52, Issue 3, Pages R257-R265Publisher
BIOSCIENTIFICA LTD
DOI: 10.1530/JME-14-0030
Keywords
breast cancer; oestrogen receptor; androgen receptors; steroid
Categories
Funding
- Prostate Cancer UK
- Cancer Research UK
- Prostate Cancer UK [S12-026] Funding Source: researchfish
Ask authors/readers for more resources
Breast cancer (BC) is traditionally viewed as an oestrogen-dependent disease in which the androgen receptor (AR) is inhibitory, counteracting the oncogenic activity of oestrogen receptor alpha (ER alpha (ESR1)). Most probably as a result of this crosstalk, the AR has prognostic value in ER-positive disease, with AR positivity reported to correlate with a better prognosis. Activation of the AR pathway has been previously used as a therapeutic strategy to treat BC, but its usage declined following the introduction of the anti-oestrogen tamoxifen. More recently, it has been demonstrated that a subset of triple-negative BCs (molecular apocrine) are dependent upon androgen signalling for growth and therapies that inhibit androgen signalling, currently used for the treatment of prostate cancer, e. g. the antiandrogen bicalutamide and the CYP17 inhibitor abiraterone acetate are undergoing clinical trials to investigate their efficacy in this BC subtype. This review summarises the current knowledge of AR activity in BC.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available